Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
At this closed symposium, sponsored by Bayer and GlaxoSmithKline, various aspects of the biology and pharmacology of NO/cGMP signaling and PDE5 were discussed, with special emphasis on newer PDE5 inhibitors and potential new therapeutics focused on NO signaling, especially endothelial and neuronal NO synthases.
